NCT06525220 2026-02-23A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)Merus B.V.Phase 3 Recruiting500 enrolled
NCT06998069 2025-12-30Head and Neck Cancer Study Project in the Geriatric PopulationBrown UniversityPhase 3 Recruiting20 enrolled
NCT07264075 2025-12-04ILLUMINEGroupe Oncologie Radiotherapie Tete et CouPhase 3 Not yet recruiting780 enrolled
NCT03358472 2025-12-03Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)Incyte CorporationPhase 3 Completed89 enrolled 14 charts
NCT03765918 2025-08-20MK-3475-689Merck Sharp & Dohme LLCPhase 3 Active not recruiting714 enrolled 90 charts 1 FDA
NCT02358031 2025-07-18MK-3475-048Merck Sharp & Dohme LLCPhase 3 Completed882 enrolled 50 charts 1 FDA